Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia
(AML) have made enormous progress during the past decades. Because AML is a rare …

Osteosarcoma is the most common bone cancer in children and young adults. Surgery and
multi-agent chemotherapy are the standard treatment regimens for this disease. New …

Preclinical and clinical development of agents that inhibit cell-cycle progression have brought
an understanding of the feasibility of targeting various cell-cycle regulators in patients with …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG–…

Background The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by
the National Cancer Institute (NCI) to identify novel therapeutic agents that may have …

Osteosarcoma (OS) is a primary malignancy of bone with a tendency to metastasize early.
Despite intensive chemotherapy and surgical resection, ∼30% of patients still develop distant …

Background MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is
currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation …

Background Rapamycin is a highly specific inhibitor of mTOR, a serine/threonine kinase that
controls cap‐dependent translation. Here we report the activity of rapamycin against the in …

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by
the pediatric preclinical testing program - Kolb - 2008 - … Anders Kolb MD … Anders Kolb MD …

Purpose: To improve the long-term event-free survival of patients with Ewing’s family of
tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a …